Search - tctmd.com

Displaying 161 - 180 of 9402

Sort: Relevancy | Date

Presentation TCT 2025

STAR: Reborn as a Primary Strategy for CTO PCI

Presenter: Taishi Hirai

October 27, 2025

Presentation TCT 2025

TCT 1000: Time Course of Ischemic and Bleeding Complications in Patients With Acute Coronary Syndrome Managed Invasively

Presenter: Fiorenzo Simonetti

October 27, 2025

Presentation TCT 2025

TCT 99: Comparative Analysis of CHA2DS2VASc, CHA2DS2VAScHSF and Mehran Risk Score for Predicting Contrast Induced Acute Kidney Injury in Stable Patients after Percutaneous Coronary Intervention

Presenter: Sami Ullah

October 27, 2025

Presentation TCT 2025

TCT 98: Elevated Calcium-Phosphate Product (CPP) is Independently Associated With Higher Cardiovascular Procedure Rates and Adverse Outcomes in Chronic Kidney Disease (CKD): A Propensity Score–Matched Analysis

Presenter: Muhammad Raffey Shabbir

October 27, 2025

Presentation TCT 2025

TCT 944: Accuracy of Artificial Intelligence Driven Prediction of Target Vessel Failure Post-PCI: A Systematic Review and Meta-Analysis

Presenter: Rahul Ravindra

October 27, 2025

Presentation TCT 2025

TCT 1003: Clinical Effectiveness of Glucagon-like peptide-1 receptor agonists on Cardiovascular outcomes Post-PCI in Type 2 Diabetes patients: Findings from the TriNetX Database

Presenter: Aymen Ahmed

October 27, 2025

Presentation TCT 2025

Blueprint for the Future of PCI with Next Generation Resorbable Technologies

Presenter: Richard J. Rapoza

October 27, 2025

Presentation TCT 2025

TCT 943: Predictors of adverse events in Patients with Premature Coronary Artery Disease undergoing PCI

Presenter: Gaurav Kumar Arora

October 27, 2025

Presentation TCT 2025

TCT 100: Patented Automated Device for Removal of Contrast From Coronary Sinus for the Prevention of Contrast Induced Nephropathy During Coronary Angiography or Intervention

Presenter: Mohammad Reza Movahed

October 27, 2025

Presentation TCT 2025

TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

Presenter: Grant William Reed

October 27, 2025

Presentation TCT 2025

TCT 940: Prognostic Role of Alpha Defensin in Predicting Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention

Presenter: Rami Abu Fanne

October 27, 2025

Presentation TCT 2025

TCT 101: Percutaneous Coronary Intervention Outcomes in African American versus Non-African American Patients on Hemodialysis: Insights from a Large Single-Center PCI Registry

Presenter: Vaishnavi Sirekulam

October 27, 2025

Presentation TCT 2025

TCT 1002: Impact of Antithrombotic Therapy Modification: Post Hoc Analysis of the EPIC CAD Trial

Presenter: Seong-Bong Wee

October 27, 2025

Presentation TCT 2025

Putting CT-Guided PCI into Practice

Presenter: Yader Sandoval

October 27, 2025

Presentation TCT 2025

The Current State of CT-Guided PCI

Presenter: Evan Shlofmitz

October 27, 2025

Presentation TCT 2025

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

Presenter: Paulo Roberto Tartuce Filho

October 27, 2025

Presentation TCT 2025

Why CT-Guided PCI Matters

Presenter: Carlos Collet

October 27, 2025

Presentation TCT 2025

TCT 998: Dual Antiplatelet Therapy (DAT) versus Triple Therapy (TAT) post Percutaneous Coronary Intervention (PCI) in patients requiring Chronic Anticoagulation: Meta-analysis.

Presenter: Kanishk Aggarwal

October 27, 2025

Presentation TCT 2025

TCT 999: One- versus three-month DAPT in patients at high or very high bleeding risk undergoing PCI: Results from the XIENCE Short DAPT Program

Presenter: Davide Cao

October 27, 2025

Presentation TCT 2025

TCT 996: One-versus three-month DAPT in High Bleeding Risk Patients With or Without Baseline Anemia Undergoing PCI

Presenter: Francesca Maria Di Muro

October 27, 2025

Advertisement

STAR: Reborn as a Primary Strategy for CTO PCI

TCT 1000: Time Course of Ischemic and Bleeding Complications in Patients With Acute Coronary Syndrome Managed Invasively

TCT 99: Comparative Analysis of CHA2DS2VASc, CHA2DS2VAScHSF and Mehran Risk Score for Predicting Contrast Induced Acute Kidney Injury in Stable Patients after Percutaneous Coronary Intervention

TCT 98: Elevated Calcium-Phosphate Product (CPP) is Independently Associated With Higher Cardiovascular Procedure Rates and Adverse Outcomes in Chronic Kidney Disease (CKD): A Propensity Score–Matched Analysis

TCT 944: Accuracy of Artificial Intelligence Driven Prediction of Target Vessel Failure Post-PCI: A Systematic Review and Meta-Analysis

TCT 1003: Clinical Effectiveness of Glucagon-like peptide-1 receptor agonists on Cardiovascular outcomes Post-PCI in Type 2 Diabetes patients: Findings from the TriNetX Database

Blueprint for the Future of PCI with Next Generation Resorbable Technologies

TCT 943: Predictors of adverse events in Patients with Premature Coronary Artery Disease undergoing PCI

TCT 100: Patented Automated Device for Removal of Contrast From Coronary Sinus for the Prevention of Contrast Induced Nephropathy During Coronary Angiography or Intervention

TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

TCT 940: Prognostic Role of Alpha Defensin in Predicting Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention

TCT 101: Percutaneous Coronary Intervention Outcomes in African American versus Non-African American Patients on Hemodialysis: Insights from a Large Single-Center PCI Registry

TCT 1002: Impact of Antithrombotic Therapy Modification: Post Hoc Analysis of the EPIC CAD Trial

Putting CT-Guided PCI into Practice

The Current State of CT-Guided PCI

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

Why CT-Guided PCI Matters

TCT 998: Dual Antiplatelet Therapy (DAT) versus Triple Therapy (TAT) post Percutaneous Coronary Intervention (PCI) in patients requiring Chronic Anticoagulation: Meta-analysis.

TCT 999: One- versus three-month DAPT in patients at high or very high bleeding risk undergoing PCI: Results from the XIENCE Short DAPT Program

TCT 996: One-versus three-month DAPT in High Bleeding Risk Patients With or Without Baseline Anemia Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content